Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

110.27 -2.21 (-1.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel. 
Via The Motley Fool
Topics Cannabis
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância... 
Via Benzinga
Topics Cannabis
Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
Cantor Fitzgerald analyst Charles C. 
Via Benzinga
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. 
Via Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors. 
Via InvestorPlace
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Is Axsome Therapeutics Stock a Screaming Buy?
The biotech could be staring down an enormous commercial opportunity. 
Via The Motley Fool
Expert Ratings for Jazz Pharmaceuticals
Via Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Recap: Jazz Pharmaceuticals Q1 Earnings
Via Benzinga
GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job
For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products. 
Via Benzinga
FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing
A bipartisan group of U.S. lawmakers reintroduceda measure on Wednesdaythat aims to secure theFood and Drug ... 
Via Benzinga
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened. 
Via Benzinga
4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Bargains are hiding in plain sight with the Nasdaq Composite still well below its November 2021 record-closing high. 
Via The Motley Fool
Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day 
Via Benzinga
10 Cannabis Stocks That Could Go Sky High In 2023
With cannabis legalization gaining momentum, investing in cannabis presents a lucrative opportunity. Investors may want to explore cannabis stocks to enhance their portfolios. Here are the top 10... 
Via Talk Markets
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 32 companies reached new 52-week lows. 
Via Benzinga
3 Cheap Growth Stocks That Are Too Good to Pass Up
These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors. 
Via InvestorPlace
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers. 
Via Benzinga
Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at... 
Via Benzinga
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical... 
Via Benzinga
World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project... 
Via Benzinga
Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022. 
Via Benzinga
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
The biotech's share price more than doubled during last year's bear market. 
Via The Motley Fool
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.